The Board of Directors of
A maximum total of 1,000,000 option rights will be issued, and they will entitle their owners to subscribe for a maximum total of 1,000,000 new shares in the company. The option rights will be issued free of charge. Shares can be subscribed to on the basis of the option rights, as follows:
- 25 % of the option rights given to the option right holder: The share subscription period begins upon the first anniversary of the Board of Directors' resolution to allocate the option rights to the option right holder;
- the remaining 75 % of the option rights given to the option right holder: The share subscription period begins monthly in installments of 1/36th per month on the last day of each month in such a way that the share subscription period for the first 1/36th installment shall begin on the last day of the next month following the first anniversary of the Board of Directors' resolution to allocate the option rights to the option right holder.
The subscription period for the shares ends on
The shares that are subscribed with the option rights to be issued will account for a total maximum of approximately 4.9 % of all the company's shares and votes after possible share subscriptions. As a result of the share subscriptions made with the option rights, the number of shares in the company may increase by a total maximum of 1,000,000 shares.
The subscription price for a share subscribed for with one option right is
The share subscription price will be credited to the company's reserve for invested unrestricted equity. The amount of dividends and distribution of assets per share paid will be deducted from the share subscription price.
The theoretical market value of one option right is approximately
The target group of the stock option plan includes approximately 35 persons. The terms and conditions of the option program are attached to this announcement.
Further enquiries
Certified adviser
Information about Bioretec
Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
Bioretec is developing the new RemeOs(TM) product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs(TM) implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their
Better healing - Better life. www.bioretec.com
https://news.cision.com/bioretec/r/bioretec-ltd-s-board-of-directors-has-decided-on-a-new-option-program-2023-1,c3857811
https://mb.cision.com/Public/20509/3857811/80aa95b532e814bc.pdf
(c) 2023 Cision. All rights reserved., source